TrialThe Lancet. Oncology2024

Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.

Douglas Adkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.